
|Articles|August 20, 2014
- Immunotherapy (Issue 3)
- Volume 3
- Issue 1
Combining Immunotherapies With Targeted Therapies and Other Immunotherapies
Author(s)Gregory A. Daniels, MD, PhD
Gregory A. Daniels, MD, PhD, discusses opportunities to combine immunotherapies with both targeted therapies and other immunotherapies.
Advertisement
Gregory A. Daniels, MD, PhD, associate clinical professor of medicine, Division of Hematology-Oncology, University of California, San Diego, discusses opportunities to combine immunotherapies with both targeted therapies and other immunotherapies. Daniels references the results of the 2007-2012 PROCLAIM National Registry, which was presented at the 2014 ASCO Annual Meeting.
Read about combining immunotherapies > >
Articles in this issue
almost 12 years ago
A Brief History of Immunotherapyalmost 12 years ago
Better Biomarker Testing Needed in Immuno-Oncologyalmost 12 years ago
Autoimmunity and Limitations of Cancer Vaccinesalmost 12 years ago
The Management of Side Effects Associated With Immunotherapiesalmost 12 years ago
The Next Wave in Immunotherapy: Combinationsalmost 12 years ago
Future Immune Checkpoint StrategiesAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































